APA (7th ed.) Citation

K, A., M, S. T., M, S., SA, J., H, S., & JS, W. (2024). Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: A randomized, single-blind, two-arm, parallel-group controlled trial. Frontiers in oncology, 14, 1357789. https://doi.org/10.3389/fonc.2024.1357789

Chicago Style (17th ed.) Citation

K, Anvari, Seilanian Toussi M, Saghafi M, Javadinia SA, Saghafi H, and Welsh JS. "Extended Dosing (12 Cycles) Vs Conventional Dosing (6 Cycles) of Adjuvant Temozolomide in Adults with Newly Diagnosed High-grade Gliomas: A Randomized, Single-blind, Two-arm, Parallel-group Controlled Trial." Frontiers in Oncology 14 (2024): 1357789. https://doi.org/10.3389/fonc.2024.1357789.

MLA (9th ed.) Citation

K, Anvari, et al. "Extended Dosing (12 Cycles) Vs Conventional Dosing (6 Cycles) of Adjuvant Temozolomide in Adults with Newly Diagnosed High-grade Gliomas: A Randomized, Single-blind, Two-arm, Parallel-group Controlled Trial." Frontiers in Oncology, vol. 14, 2024, p. 1357789, https://doi.org/10.3389/fonc.2024.1357789.